MedTrace Logo

DHA (Docosahexaenoic Acid), an Omega 3 Fatty Acid, in Slowing the Progression of Alzheimer's Disease

NCT00440050 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 402

Last updated 2014-09-25

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether chronic DHA (Docosahexaenoic Acid) supplementation slows the progression of cognitive and functional decline in mild to moderate Alzheimer's disease (AD).

Conditions

Interventions

DRUG

DHA (Docosahexaenoic Acid)

950 mg soft-gel capsules which contain approximately 510 mg DHA, 2 capsules twice a day for 18 months

DRUG

Placebo

2 placebo capsules twice a day for 18 months

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • DSM Nutritional Products, Inc.

    collaborator INDUSTRY

  • Alzheimer's Disease Cooperative Study (ADCS)

    lead OTHER

Principal Investigators

  • Joseph Quinn, MD · Oregon Health and Science University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2009-05-31
Completion
2009-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00440050 on ClinicalTrials.gov